Caring Brands' Losses Mount Amidst Strategic Relaunch Plans

Ticker: CABR · Form: 10-K · Filed: Mar 31, 2026 · CIK: 0002020737

Caring Brands, INC. 10-K Filing Summary
FieldDetail
CompanyCaring Brands, INC. (CABR)
Form Type10-K
Filed DateMar 31, 2026
Risk Levelhigh
Pages15
Reading Time18 min
Key Dollar Amounts$0.001, $6,278,191, $1,517,431, $1.9billion, $3.23billion
Sentimentbearish

Sentiment: bearish

Topics: Wellness Products, OTC, Cosmetics, Phototherapy, Vitiligo Treatment, Psoriasis Treatment, Product Relaunch, Market Expansion, Net Loss

TL;DR

**CABR is burning cash with mounting losses, and its future hinges on a risky U.S. relaunch of a previously failed product, making it a speculative bet.**

AI Summary

Caring Brands, Inc. (CABR) reported nominal revenues and a net loss of $6,278,191 for the fiscal year ended December 31, 2025, a significant increase from the $1,517,431 net loss in 2024. The company, a wellness consumer products firm, focuses on OTC and cosmetic products, including hair loss, eczema, psoriasis, vitiligo, and suncare solutions. Its flagship product, Photocil, a narrow-band UV filter for vitiligo and psoriasis, was relaunched in India in Q3 2022 and is targeted for a 2026 relaunch in the U.S. after being removed in February 2023 due to insufficient sales. CABR is exploring sub-licensing opportunities for Photocil across numerous countries in Asia, the Middle East, and Africa. The global phototherapy treatment market is projected to grow from $1.9 billion in 2023 to $3.23 billion by 2033, with India's market expanding at an estimated CAGR of 7.8%. The company's Hair Enzyme Booster (JW-700) is also being manufactured and sold in India. As of June 30, 2025, the aggregate market value of common stock held by non-affiliates was approximately $3,955,388.

Why It Matters

Caring Brands' substantial net loss of $6.28 million in 2025, up from $1.52 million in 2024, signals significant operational challenges for investors. The company's reliance on a 2026 U.S. relaunch of Photocil, a product previously pulled due to poor sales, introduces considerable market risk and competitive pressure from established dermatology treatments. For employees, the company's financial instability and dependence on future product adoption could impact job security and growth opportunities. Customers might see innovative products like Photocil, but its past market failure raises questions about future efficacy and marketing strategies in a competitive wellness market.

Risk Assessment

Risk Level: high — Caring Brands reported a net loss of $6,278,191 in 2025, a 314% increase from the $1,517,431 loss in 2024, indicating significant financial deterioration. The company also had 'nominal revenues,' suggesting a lack of sustainable income streams. Furthermore, its key product, Photocil, was removed from the U.S. market in February 2023 due to 'insufficient sales,' highlighting past commercialization failures and future market adoption uncertainty.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment given the substantial and increasing net losses and 'nominal revenues.' Await concrete evidence of successful U.S. market re-entry for Photocil and significant revenue generation before considering any position.

Key Numbers

Key Players & Entities

FAQ

What were Caring Brands, Inc.'s revenues and net income for the fiscal year 2025?

Caring Brands, Inc. reported nominal revenues and a net loss of $6,278,191 for the fiscal year ended December 31, 2025. This represents a significant increase in loss compared to the $1,517,431 net loss reported in 2024.

What is Photocil and why was it removed from the U.S. market by Caring Brands?

Photocil is a narrow-band UV filter product designed for the treatment of vitiligo and psoriasis. It was briefly launched in the United States from December 2022 until February 2023 but was subsequently removed due to insufficient sales, primarily attributed to the lack of a dedicated sales and marketing team.

When does Caring Brands, Inc. plan to relaunch Photocil in the United States?

Caring Brands, Inc. is currently preparing for the relaunch of Photocil in the United States, which is targeted for 2026. The company is exploring manufacturing and marketing options for this relaunch.

What is the projected growth of the global phototherapy treatment market, relevant to Caring Brands?

The global phototherapy treatment market is projected to grow from approximately $1.9 billion in 2023 to $3.23 billion by 2033, at a Compound Annual Growth Rate (CAGR) of around 5.2%. The Indian market is expected to expand even faster, with an estimated CAGR of approximately 7.8%.

What are the primary risks associated with Caring Brands' business strategy?

Primary risks include the company's 'nominal revenues' and substantial net losses, indicating financial instability. The reliance on a successful U.S. relaunch of Photocil, a product that previously failed due to insufficient sales, presents significant market adoption and execution risks. Additionally, market growth projections for phototherapy treatments are subject to various external factors beyond the company's control.

How many shares of common stock did Caring Brands, Inc. have outstanding as of March 30, 2026?

As of March 30, 2026, Caring Brands, Inc. had 12,341,506 shares of its common stock outstanding. The company is authorized to issue a total of 100,000,000 shares of common stock with a par value of $0.001.

What is the regulatory status of Photocil in the United States and India?

In the United States, Photocil is categorized as an OTC product using a USP monographed ingredient as a skin protectant, with FDA-registered labeling. It does not require FDA pre-market approval as it uses GRASE ingredients. In India, Photocil is currently marketed as an OTC product compliant with local cosmetic regulations.

What is the market opportunity for vitiligo treatments globally and in India, according to the filing?

The global vitiligo treatment market was valued at approximately $538.90 million in 2024 and is projected to reach $807.70 million by 2034, growing at a CAGR of 4.60%. In India, the prevalence of vitiligo ranges from 0.25% to 4% of the population, and can reach as high as 8.8% in certain regions, indicating a significant potential market opportunity.

Who is Caring Brands' licensee for Photocil in India and what are their expansion plans?

Caring Brands' licensee in India is Cosmofix and San Pellegrino Cosmetics. They are currently exploring additional sub-licensing opportunities for Photocil in numerous countries across Asia (e.g., Nepal, Bangladesh, Vietnam), the Middle East (e.g., UAE, Saudi Arabia), and Africa (e.g., Egypt, Nigeria).

What is the significance of the 'nominal revenues' reported by Caring Brands, Inc.?

The 'nominal revenues' reported by Caring Brands, Inc. indicate that the company is generating very little sales income. This, combined with a net loss of over $6.2 million in 2025, suggests that the company is not yet commercially viable and is heavily reliant on external funding or future product success to sustain operations.

Risk Factors

Industry Context

Caring Brands, Inc. operates in the wellness consumer products sector, focusing on dermatological solutions for conditions like hair loss, eczema, psoriasis, and vitiligo. The company's strategy involves leveraging phototherapy treatments, a market projected to grow significantly from $1.9 billion in 2023 to $3.23 billion by 2033. Competition exists within the broader psoriasis and vitiligo treatment markets, with the psoriasis market valued at $34 billion and the vitiligo market at $538.90 million in recent periods.

Regulatory Implications

As a producer of OTC and cosmetic products for specific medical conditions, Caring Brands, Inc. is subject to stringent regulatory oversight. Compliance with health and safety regulations for product development, manufacturing, and marketing is critical. Any changes in regulatory frameworks for pharmaceuticals or cosmetics in its target markets, particularly in the U.S. and Asia, could impact product approvals, market access, and sales.

What Investors Should Do

  1. Monitor U.S. Photocil relaunch progress and initial sales data.
  2. Evaluate the financial performance trends, particularly the increasing net loss.
  3. Assess the success of international sub-licensing and manufacturing efforts in India.
  4. Analyze the competitive landscape and market penetration strategies for Photocil and JW-700.

Key Dates

Glossary

OTC
Over-the-counter, referring to products that can be sold directly to consumers without a prescription from a healthcare professional. (Indicates the type of products Caring Brands, Inc. focuses on, which are generally accessible to a broad consumer base.)
Phototherapy
A type of medical treatment that uses specific wavelengths of light to treat skin conditions. (Directly relates to the company's flagship product, Photocil, and the market segment it operates within.)
CAGR
Compound Annual Growth Rate, a measure of the average annual growth rate of an investment over a specified period of time longer than one year. (Used to project the growth of the phototherapy market, providing context for the company's market potential.)
Narrow-band UV filter
A component in devices that emits ultraviolet light within a specific, limited range of wavelengths, often used in dermatological treatments. (Describes the technology behind the company's key product, Photocil.)
Sub-licensing
The process where a licensee grants rights to a third party to use the licensed intellectual property, often within specific territories or for specific applications. (Highlights the company's strategy for expanding the reach of its products into new international markets.)

Year-Over-Year Comparison

The most recent 10-K filing indicates a significant deterioration in financial performance, with the net loss widening from $1,517,431 in 2024 to $6,278,191 in 2025. While specific revenue figures for 2025 are not detailed here, the increased loss suggests either declining revenues or escalating costs. The company continues to focus on product relaunches and international market expansion, but the increased net loss highlights the challenges in achieving profitability and positive revenue growth.

Filing Stats: 4,454 words · 18 min read · ~15 pages · Grade level 12 · Accepted 2026-03-31 08:44:29

Key Financial Figures

Filing Documents

Business

Business 1 Item 1A. Risk Factors 16 Item 1B. Unresolved Staff Comments 34 Item 1C. Cybersecurity 34 Item 2.

Properties

Properties 34 Item 3.

Legal Proceedings

Legal Proceedings 34 Item 4. Mine Safety Disclosures 34 PART II 35 Item 5. Market for Company's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities 35 Item 6. [RESERVED] 35 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 35 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 41 Item 8. Consolidated Financial Statements and Supplementary Data 41 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosures 41 Item 9A. Control and Procedures 41 Item 9B. Other Information 41 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 41 PART III 42 Item 10. Directors, Executive Officers and Corporate Governance 42 Item 11.

Executive Compensation

Executive Compensation 47 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 50 Item 13. Certain Relationships and Related Transactions, and Director Independence 51 Item 14. Principal Accounting Fees and Services 54 PART IV 55 Item 15. Exhibit and and Financial Disclosures 55 Item 16. Form 10-K Summary 55

Signatures

Signatures 56 i CAUTIONARY This annual report contains forward-looking statements that are based on our management's beliefs, expectations, and assumptions and on information currently available to us. All statements other than statements of historical facts are forward-looking statements. The

forward-looking statements are contained in, but not limited to, the sections entitled " Risk Factors ," " Management's

forward-looking statements are contained in, but not limited to, the sections entitled " Risk Factors ," " Management's Discussion and Analysis of Financial Condition and Results of Operations " and " Business ." These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: our goal and strategies; our future business development, financial condition and results of operations; expected changes in our revenue, costs or expenditures; growth of and competition trends in our industry; our expectations regarding demand for, and market acceptance of, our products; our expectations regarding our relationships with investors, institutional funding partners and other parties with whom we collaborate; fluctuations in general economic and business conditions in the markets in which we operate; and relevant government policies and regulations relating to our industry. In some cases, you can identify forward-looking statements by terms such as "may," "could," "will," "should," "would," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "project" or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the he

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing